Free Trial

Inozyme Pharma (INZY) SEC Filings & 10K Form

Inozyme Pharma logo
$0.87 -0.03 (-3.53%)
As of 11:47 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Recent Inozyme Pharma SEC Filings

DateFilerForm TypeView
04/03/2025
3:27 PM
Inozyme Pharma (Issuer)
Treco Douglas A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2025
3:27 PM
Inozyme Pharma (Issuer)
Subramanian Sanjay (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2025
3:29 PM
Inozyme Pharma (Issuer)
Winton Matthew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/17/2025
3:24 PM
Inozyme Pharma (Issuer)
Treco Douglas A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/17/2025
3:25 PM
Inozyme Pharma (Issuer)
Winton Matthew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/17/2025
3:26 PM
Inozyme Pharma (Issuer)
Subramanian Sanjay (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/10/2025
4:17 PM
Inozyme Pharma (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/10/2025
7:31 AM
Inozyme Pharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/10/2025
7:31 AM
Inozyme Pharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/10/2025
7:32 AM
Inozyme Pharma (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/10/2025
7:32 AM
Inozyme Pharma (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/14/2025
12:59 PM
Inozyme Pharma (Subject)
SAMLYN CAPITAL, LLC (Filed by)
Form SCHEDULE 13G/A
01/10/2025
7:06 AM
Inozyme Pharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/14/2024
11:19 AM
EVENTIDE ASSET MANAGEMENT, LLC (Filed by)
Inozyme Pharma (Subject)
Form SC 13G/A
11/05/2024
7:33 AM
Inozyme Pharma (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/05/2024
7:31 AM
Inozyme Pharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/24/2024
3:34 PM
Inozyme Pharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/24/2024
1:02 PM
BlackRock, Inc. (Filed by)
Inozyme Pharma (Subject)
Form SC 13G
10/03/2024
7:58 PM
Inozyme Pharma (Issuer)
Treco Douglas A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/03/2024
7:57 PM
Inozyme Pharma (Issuer)
Winton Matthew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/06/2024
3:52 PM
Inozyme Pharma (Filer)
Form 424B5
08/06/2024
3:54 PM
Inozyme Pharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/20/2024
3:30 PM
Inozyme Pharma (Issuer)
Mathers Edward T (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2024
3:15 PM
Hopfner Robert Lorne (Reporting)
Inozyme Pharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2024
3:20 PM
Inozyme Pharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/07/2024
7:32 AM
Inozyme Pharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/07/2024
7:33 AM
Inozyme Pharma (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/08/2024
5:44 AM
Inozyme Pharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Remove Ads

Related Companies and Tools


This page (NASDAQ:INZY) was last updated on 4/8/2025 by MarketBeat.com Staff
From Our Partners